rintatolimod

June 14, 2019June 14, 2019

First Patient Dosed in Phase 2 Trial Evaluating Ampligen-Keytruda-Chemo Combo for Ovarian Cancer

News

The first patient has been dosed with Hemispherx Biopharma‘s experimental treatment Ampligen (rintatolimod), in combination with Keytruda (pembrolizumab) and cisplatin, for recurrent ovarian cancer. The investigator-sponsored Phase 2 trial (NCT03734692) is ... Read more

March 1, 2019

UPMC Trial to Explore Ampligen Combo for Recurrent Ovarian Cancer

News

A new investigator-sponsored clinical trial is recruiting women with recurrent, platinum-sensitive ovarian cancer to study a combination of Hemispherx Biopharma’s investigational product Ampligen (rintatolimod) plus chemo-immunotherapy, the company announced. The Phase 1/2 trial ... Read more